ENDRA Life Sciences Inc. has released preliminary estimates for its financial performance in the quarter ended June 30, 2025. The company expects to report no revenue for this period, consistent with the results from the same quarter in 2024. ENDRA anticipates a reduction in its loss from operations, estimating a loss of approximately $1.3 million, compared to a net loss of approximately $2.2 million in the corresponding quarter of the previous year. As of June 30, 2025, ENDRA's total assets are expected to be approximately $2.6 million, with working capital of approximately $1.2 million. The company also reported having $1.8 million in cash and cash equivalents at the end of the quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-007893), on July 09, 2025, and is solely responsible for the information contained therein.